Literature DB >> 17117158

The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells.

Petar N Grozdanov1, Mladen I Yovchev, Mariana D Dabeva.   

Abstract

Glypican-3 (Gpc3), a cell surface-linked heparan sulfate proteoglycan is highly expressed during embryogenesis and is involved in organogenesis. Its exact biological function remains unknown. We have studied the expression of Gpc3 in fetal and adult liver, in liver injury models of activation of liver progenitor cells: D-galactosamine and 2-acetylaminofluorene (2-AAF) administration followed by partial hepatectomy (PH) (2-AAF/PH); and in the Solt-Farber carcinogenic model: by initiation with a single dose of diethylnitrosamine and promotion with 2-AAF followed by PH treatment. Gpc3 expression was studied using complementary DNA microarrays, reverse transcriptase-polymerase chain reaction, in situ hybridization (ISH); ISH combined with immunohistochemistry (IHC) and immunofluorescent microscopy. We found that Gpc3 is highly expressed in fetal hepatoblasts from embryonic days 13 through 16 and its expression gradually decreases towards birth. Dual ISH with Gpc3 and alpha-fetoprotein (AFP) probes confirmed that only hepatoblasts and no other fetal liver cells express Gpc3. At 3 weeks after birth the expression of Gpc3 mRNA and protein was hardly detected in the liver. Gpc3 expression was highly induced in oval cell of D-gal and 2-AAF/PH treated animals. Dual ISH/IHC with Gpc3 riboprobe and cytokeratin-19 (CK-19) antibody revealed that Gpc3 is expressed in activated liver progenitor cells. ISH for Gpc3 and AFP performed on serial liver sections also showed coexpression of the two-oncofetal proteins. FACS isolated oval cells with anti-rat Thy1 revealed expression of Gpc3. Gpc3 expression persists in atypical duct-like structures and liver lesions of animals subjected to the Solt-Farber model of initiation and promotion of liver cancer expressing CK-19. In this work we report for the first time that the oncofetal protein Gpc3 is a marker of hepatic progenitor cells and of early liver lesions. Our findings show further that hepatic progenitor/oval cells are the target for malignant transformation in the Solt-Farber model of hepatic carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17117158     DOI: 10.1038/labinvest.3700479

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  38 in total

1.  Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma.

Authors:  Juan-Ping Yu; Xi-Guang Xu; Rui-Juan Ma; Shi-Ni Qin; Cong-Rong Wang; Xiao-Bo Wang; Ming Li; Ming-Song Li; Qiang Ma; Wei-Wen Xu
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

2.  Thy1-positive cells have bipotential ability to differentiate into hepatocytes and biliary epithelial cells in galactosamine-induced rat liver regeneration.

Authors:  Junko Kon; Norihisa Ichinohe; Hidekazu Ooe; Qijie Chen; Kazunori Sasaki; Toshihiro Mitaka
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

Review 3.  Are hematopoietic stem cells involved in hepatocarcinogenesis?

Authors:  Antonio Facciorusso; Matteo Antonino; Valentina Del Prete; Viviana Neve; Maria Principia Scavo; Michele Barone
Journal:  Hepatobiliary Surg Nutr       Date:  2014-08       Impact factor: 7.293

4.  Profiling of differentially expressed microRNAs (miRNAs) during differentiation of rat hepatic oval cells (HOCs) into hepatocellular carcinoma (HCC) cells.

Authors:  R H Xu; L Y Zheng; D L He; J Meng; L P Xia; X B Hao; Z Z Zhang
Journal:  Clin Transl Oncol       Date:  2014-09-26       Impact factor: 3.405

5.  Bone marrow-derived mesenchymal stem cells inhibits hepatocyte apoptosis after acute liver injury.

Authors:  Yijing Cai; Zhuolin Zou; Liyuan Liu; Si Chen; Yi Chen; Zhuo Lin; Keqing Shi; Lanman Xu; Yongping Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

6.  Suppression of liver regeneration and hepatocyte proliferation in hepatocyte-targeted glypican 3 transgenic mice.

Authors:  Bowen Liu; Aaron W Bell; Shirish Paranjpe; William C Bowen; Jaspal S Khillan; Jian-Hua Luo; Wendy M Mars; George K Michalopoulos
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 7.  The origin, biology, and therapeutic potential of facultative adult hepatic progenitor cells.

Authors:  Soona Shin; Klaus H Kaestner
Journal:  Curr Top Dev Biol       Date:  2014       Impact factor: 4.897

Review 8.  Liver regeneration: alternative epithelial pathways.

Authors:  George K Michalopoulos
Journal:  Int J Biochem Cell Biol       Date:  2009-09-27       Impact factor: 5.085

9.  Keratin 19 marks poor differentiation and a more aggressive behaviour in canine and human hepatocellular tumours.

Authors:  Renee G H M van Sprundel; Ted S G A M van den Ingh; Valeer J Desmet; Azeam Katoonizadeh; Louis C Penning; Jan Rothuizen; Tania Roskams; Bart Spee
Journal:  Comp Hepatol       Date:  2010-02-18

10.  Investigation of the role of glypican 3 in liver regeneration and hepatocyte proliferation.

Authors:  Bowen Liu; Shirish Paranjpe; William C Bowen; Aaron W Bell; Jian-Hua Luo; Yan-Ping Yu; Wendy M Mars; George K Michalopoulos
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.